694 related articles for article (PubMed ID: 25703571)
1. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
Hawn TR; Shah JA; Kalman D
Immunol Rev; 2015 Mar; 264(1):344-62. PubMed ID: 25703571
[TBL] [Abstract][Full Text] [Related]
2. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
3. Host-Directed Therapeutics as a Novel Approach for Tuberculosis Treatment.
Kim YR; Yang CS
J Microbiol Biotechnol; 2017 Sep; 27(9):1549-1558. PubMed ID: 28683527
[TBL] [Abstract][Full Text] [Related]
4. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
Palucci I; Delogu G
Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
[TBL] [Abstract][Full Text] [Related]
5. Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches.
Mehta K; Spaink HP; Ottenhoff THM; van der Graaf PH; van Hasselt JGC
Trends Pharmacol Sci; 2022 Apr; 43(4):293-304. PubMed ID: 34916092
[TBL] [Abstract][Full Text] [Related]
6. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?
Park HE; Lee W; Shin MK; Shin SJ
Front Immunol; 2021; 12():703060. PubMed ID: 34262571
[TBL] [Abstract][Full Text] [Related]
7. TB drug development: immunology at the table.
Nathan C; Barry CE
Immunol Rev; 2015 Mar; 264(1):308-18. PubMed ID: 25703568
[TBL] [Abstract][Full Text] [Related]
8. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
Abreu R; Giri P; Quinn F
Front Immunol; 2020; 11():1553. PubMed ID: 32849525
[TBL] [Abstract][Full Text] [Related]
9. The Macrophage Response to
Maphasa RE; Meyer M; Dube A
Front Cell Infect Microbiol; 2020; 10():618414. PubMed ID: 33628745
[TBL] [Abstract][Full Text] [Related]
10. Harnessing host-pathogen interactions for innovative drug discovery and host-directed therapeutics to tackle tuberculosis.
Saini S; Gangwar A; Sharma R
Microbiol Res; 2023 Oct; 275():127466. PubMed ID: 37531813
[TBL] [Abstract][Full Text] [Related]
11. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
Marimani M; Ahmad A; Duse A
Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
[TBL] [Abstract][Full Text] [Related]
12. The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection.
Giraud-Gatineau A; Coya JM; Maure A; Biton A; Thomson M; Bernard EM; Marrec J; Gutierrez MG; Larrouy-Maumus G; Brosch R; Gicquel B; Tailleux L
Elife; 2020 May; 9():. PubMed ID: 32369020
[TBL] [Abstract][Full Text] [Related]
13. Host-Directed Therapeutics against Mycobacterial Infections.
Tomioka H; Sano C; Tatano Y
Curr Pharm Des; 2017; 23(18):2644-2656. PubMed ID: 27908271
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against
Palucci I; Maulucci G; De Maio F; Sali M; Romagnoli A; Petrone L; Fimia GM; Sanguinetti M; Goletti D; De Spirito M; Piacentini M; Delogu G
Front Immunol; 2019; 10():3042. PubMed ID: 32038614
[TBL] [Abstract][Full Text] [Related]
15. Remembering the Host in Tuberculosis Drug Development.
Frank DJ; Horne DJ; Dutta NK; Shaku MT; Madensein R; Hawn TR; Steyn AJC; Karakousis PC; Kana BD; Meintjes G; Laughon B; Tanvir Z
J Infect Dis; 2019 Apr; 219(10):1518-1524. PubMed ID: 30590592
[TBL] [Abstract][Full Text] [Related]
16. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
17. Modulating Iron for Metabolic Support of TB Host Defense.
Phelan JJ; Basdeo SA; Tazoll SC; McGivern S; Saborido JR; Keane J
Front Immunol; 2018; 9():2296. PubMed ID: 30374347
[TBL] [Abstract][Full Text] [Related]
18. Cytokine and lipid mediator networks in tuberculosis.
Mayer-Barber KD; Sher A
Immunol Rev; 2015 Mar; 264(1):264-75. PubMed ID: 25703565
[TBL] [Abstract][Full Text] [Related]
19. Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks.
Tomioka H; Tatano Y; Sano C; Shimizu T
J Infect Chemother; 2011 Jun; 17(3):302-17. PubMed ID: 21243398
[TBL] [Abstract][Full Text] [Related]
20. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
